1 research outputs found
The prognostic impact of t(11;14) in multiple myeloma: A realâworld analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)
Abstract The prognostic impact of t(11;14) in multiple myeloma (MM) needs to be better understood to inform future treatment decisions. The Australian Lymphoma Leukaemia Group embarked on a retrospective, observational cohort study using realâworld data to interrogate treatment patterns and outcomes in 74 MM patients with t(11;14) [t(11;14)âMM] diagnosed over 10 years. This was compared to 159 and 111 MM patients with highârisk IgH translocations (IgH HRâMM) and hyperdiploidy (HyperdiploidâMM), respectively, from the Australian Myeloma and Related Diseases Registry. No appreciable differences in age, gender, ISS, LDH levels, 1q21 or del(17p) status, or treatment patterns were observed between groups. Median PFSâ1 was not different between groups but both t(11;14)âMM and IgH HRâMM had an inferior PFSâ2 vs. HyperdiploidâMM: median PFSâ2 8.2 months, 10.0 months, and 19.8 months (p = 0.002), respectively. The 3âyear OS were 69%, 71%, and 82% (p = 0.026), respectively. In the t(11;14)âMM group, gain or amplification of 1q21 at diagnosis predicted for poorer OS (HR 3.46, p = 0.002). Eleven patients had received venetoclax with 45% achieving better than a very good partial response. Results suggest that t(11;14) MM may confer an unfavorable risk profile and that the use of targeted therapies such as venetoclax earlier in the treatment algorithm should be explored